ArticleThe Journal of infectious diseases2022
Development of Inapparent Dengue Associated With Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in Cambodia.
Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03534245 (Investigating Vector-borne Determinants of Aedes-transmitted Arboviral Infections in Cambodia), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating Vector-borne Determinants of Aedes-transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Antibody response to Aedes aegypti D7L1 + 2 salivary proteins as marker of aggregate vector exposure and correlate of dengue virus susceptibility.PLoS neglected tropical diseases · 2025Article
- Seroprevalence of Dengue, Zika, and Chikungunya Viruses in Humans and Colocated Macaques in Thailand and Cambodia.The Journal of infectious diseases · 2025Article
- Immunity to Non-Dengue Flaviviruses Impacts Dengue Virus Immunoglobulin G Enzyme-Linked Immunosorbent Assay Specificity in Cambodia.The Journal of infectious diseases · 2025Observational
- Unraveling the Molecular Mechanisms of Mosquito Salivary Proteins: New Frontiers in Disease Transmission and Control.Biomolecules · 2025Review
- Clinical efficacy of mechanically activated tissue retractor combined with vacuum sealing drainage for treating deep soft tissue defects: a prospective study.American journal of translational research · 2025Article
- Review of dengue vectors in Cambodia: distribution, bionomics, vector competence, control and insecticide resistance.Parasites & vectors · 2024Review
- Climate, demography, immunology, and virology combine to drive two decades of dengue virus dynamics in Cambodia.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Antibodies toFrontiers in immunology · 2024Article
- Severe dengue in the intensive care unit.Journal of intensive medicine · 2024Review
- National dengue surveillance, Cambodia 2002-2020.Bulletin of the World Health Organization · 2023Article
- Novel approaches for the rapid development of rationally designed arbovirus vaccines.One health (Amsterdam, Netherlands) · 2023Article
- Mosquito Salivary Proteins and Arbovirus Infection: From Viral Enhancers to Potential Targets for Vaccines.Pathogens (Basel, Switzerland) · 2023Review
- Flying under the radar - impact and factors influencing asymptomatic DENV infections.Frontiers in cellular and infection microbiology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundWe established the first prospective cohort to understand how infection with dengue virus is influenced by vector-specific determinants such as humoral immunity to Aedes aegypti salivary proteins.
methodsChildren aged 2-9 years were enrolled in the PAGODAS (Pediatric Assessment Group of Dengue and Aedes Saliva) cohort with informed consent by their guardians. Children were followed semi-annually for antibodies to dengue and to proteins in Ae. aegypti salivary gland homogenate using enzyme-linked immunosorbent assays and dengue-specific neutralization titers. Children presented with fever at any time for dengue testing.
resultsFrom 13 July to 30 August 2018, we enrolled 771 children. At baseline, 22% (173/770) had evidence of neutralizing antibodies to 1 or more dengue serotypes. By April 2020, 51 children had symptomatic dengue while 148 dengue-naive children had inapparent dengue defined by neutralization assays. In a multivariate model, individuals with higher antibodies to Ae. aegypti salivary proteins were 1.5 times more likely to have dengue infection (hazard ratio [HR], 1.47 [95% confidence interval {CI}, 1.05-2.06]; P = .02), particularly individuals with inapparent dengue (HR, 1.64 [95% CI, 1.12-2.41]; P = .01).
conclusionsHigh levels of seropositivity to Ae. aegypti salivary proteins are associated with future development of dengue infection, primarily inapparent, in dengue-naive Cambodian children. CLINICAL TRIALS REGISTRATION: NCT03534245.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.